Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
According to a Bloomberg report, two private equity firms, In October 2023, Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development pipeline and cut costs.
2023年10月，賽諾菲安萬特公司（納斯達克:SNY）宣佈計劃將其消費者保健業務拆分，法國藥品公司概述了其戰略更新，以增加投資於藥物開發管線並削減成本。
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
賽諾菲表示，這一分拆將使其能夠更加專注於創新藥物和疫苗。
Sanofi's consumer health unit boasts a portfolio that includes popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.
賽諾菲的消費者健康部門擁有包括Phytoxil止咳糖漿、Icy Hot止痛凝膠和Dulcolax瀉藥片在內的熱門非處方產品組合。
According to a Bloomberg report, two private equity firms, Clayton Dubilier & Rice and PAI Partners, made separate bids for Sanofi's consumer health division.
根據彭博社的一份報告，兩家股權投資公司Clayton Dubilier & Rice和PAI Partners分別對賽諾菲的消費者健康部門進行了獨立競標。
The update pushes the European pharma giant closer to one of the largest European deals this year, which could value the unit at 15 billion euros ($16.8 billion) or more, the Bloomberg report added.
該更新將使這家歐洲製藥巨頭更接近今年歐洲最大交易之一，這筆交易可能使該部門的估值達到150億歐元（168億美元）或更高，報道補充道。
The separation is expected to occur by Q4 2024 by creating a publicly listed entity headquartered in France.
預計分拆將於2024年第四季度發生，通過創建總部位於法國的上市實體。
In July, Goldman Sachs Group Inc. (NYSE:GS) and Morgan Stanley (NYSE:MS) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring Sanofi's consumer health division.
7月，高盛集團（紐約證交所:GS）和摩根士丹利（紐約證交所:MS）表示他們正準備爲有意收購賽諾菲消費者健康部門的潛在買家安排超過650億美元（600億歐元）的債務融資。
The move highlighted banks' interest in supporting leveraged buyouts through pre-arranged financing.
此舉突顯了銀行對通過預先安排融資支持槓桿收購的興趣。
Sanofi may opt for a spinoff of its consumer health business if the offers aren't appealing, Bloomberg noted, citing sources. A company spokesperson told Bloomberg that Sanofi is evaluating potential separation options, with the earliest possible transaction happening in the fourth quarter of this year, and noted that preparations are progressing as planned.
如果報價不理想，賽諾菲可能選擇剝離其消費業務，彭博社援引消息人士稱。該公司發言人告訴彭博社，賽諾菲正在評估潛在的分離選擇，最早可能在今年第四季度發生交易，並指出準備工作正在按計劃進行。
In November 2023, Sanofi reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over $20 billion.
據悉，賽諾菲於2023年11月與Rothschild & Co.展開談判，探討將其消費保健部門剝離的可能性，這可能使該業務的價值超過200億美元。
Rival pharma giants GSK Plc (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) split their consumer healthcare units Haleon Plc (NYSE:HLN) and Kenvue Inc (NYSE:KVUE), respectively.
競爭對手製藥巨頭葛蘭素Smith克萊恩公司（紐交所：GSK）和強生公司（紐交所：JNJ）分拆了其消費保健部門，分別爲海倫公司（紐交所：HLN）和肯維公司（紐交所：KVUE）。
Price Action: SNY stock closed at $57.62 on Tuesday.
股價走勢：賽諾菲股票週二收盤價爲57.62美元。